<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01233102</url>
  </required_header>
  <id_info>
    <org_study_id>SIBS-IHS-20101010</org_study_id>
    <secondary_id>2010CB945600</secondary_id>
    <nct_id>NCT01233102</nct_id>
  </id_info>
  <brief_title>Mesenchymal Stem Cells Treat Liver Cirrhosis</brief_title>
  <official_title>Umbilical Cord Mesenchymal Stem Cell Transfusion in Patients With Severe Liver Cirrhosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yufang Shi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Soochow University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chinese Academy of Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the efficacy of umbilical cord mesenchymal stem
      cells (MSCs) transfusion in the treatment of liver cirrhosis. Liver function will be
      monitored by serum analysis. The levels of serum alanine aminotransferase (ALT), total
      bilirubin (TB), prothrombin time (PT), prealbumin(PA) and albumin (ALB) will be examined at
      pre-transfusion, and 3 days to 2 years post-transfusion. Child-Pugh scores, Model for
      End-Stage Liver Disease scores and clinical symptoms will be assessed simultaneously.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with liver cirrhosis will be randomly divided into three groups. Umbilical cord MSCs
      will be infused to patients using interventional method via hepatic artery for one group. The
      catheter will be inserted to proper hepatic artery. After the catheter placement confirmed by
      angiography, umbilical cord MSCs will be infused slowly in 20-30 minutes. Umbilical cord MSCs
      will be infused intravenously slowly in 30-60 minutes in the intravenous infusion group. The
      control group will receive conserved therapy. The levels of serum alanine aminotransferase
      (ALT), total bilirubin (TB), prothrombin time (PT), prealbumin(PA)and albumin (ALB) will be
      examined at re-transplantation, and 3 days to 2 years post-transplantation. The efficacy of
      umbilical cord MSCs transfusion will be investigated. The efficacy of different
      interventional therapies will also be compared.
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The level of serum alanine aminotransferase (ALT）</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The level of serum total bilirubin (TB)</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The level of serum prothrombin time (PT)</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The level of serum prealbumin(PA)</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The level of serum albumin (ALB)</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>liver biopsy</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The level of serum alanine aminotransferase (ALT）</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The level of serum total bilirubin (TB)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The level of serum prothrombin time (PT)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The level of serum albumin (ALB)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Liver Cirrhosis</condition>
  <arm_group>
    <arm_group_label>Conserved Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Conserved Therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Interventional Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with liver cirrhosis will be randomly divided into three groups.
1. Umbilical cord MSCs will be infused to patients using interventional method via hepatic artery for one group.2. Umbilical cord MSCs will be infused to patients intravenously for another group. The control group will receive conserved therapy. The efficacy of different interventional therapies will be compared.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Conserved Therapy</intervention_name>
    <description>Conserved Therapy</description>
    <arm_group_label>Conserved Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Hepatic artery infusion or Intravenous infusion</intervention_name>
    <description>Patients with liver cirrhosis will be randomly divided into three groups. Umbilical cord MSCs will be infused to patients using interventional method via hepatic artery for one group. The catheter will be inserted to proper hepatic artery. After the catheter placement confirmed by angiography, umbilical cord MSCs will be infused slowly in 20-30 minutes. Umbilical cord MSCs will be infused intravenously slowly for 30-60 minutes in the intravenous infusion group. The control group will receive conserved therapy.</description>
    <arm_group_label>Interventional Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-70 years.

          -  Imaging evidences of liver cirrhosis.

          -  Child-Plough score of 8 or more.

          -  Model for End-Stage Liver Disease score of 20 or more.

        Exclusion Criteria:

          -  Liver tumor on ultrasonography, CT or MRI examination.

          -  Problems in organs other than liver (e.g. heart or lungs).

          -  History of moderate to severe hepatic encephalopathy or variceal bleeding.

          -  Imaging evidences of vascular thromboses.

          -  Coma.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yufang Shi, PhD,DVM</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese Academy of Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jianhe Gan, MD</last_name>
    <role>Study Chair</role>
    <affiliation>The First Affiliated Hospital of Soochow University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>First Affiliated Hospital of Soochow University</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <zip>215006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Ren G, Zhang L, Zhao X, Xu G, Zhang Y, Roberts AI, Zhao RC, Shi Y. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell. 2008 Feb 7;2(2):141-50. doi: 10.1016/j.stem.2007.11.014.</citation>
    <PMID>18371435</PMID>
  </reference>
  <reference>
    <citation>Terai S, Ishikawa T, Omori K, Aoyama K, Marumoto Y, Urata Y, Yokoyama Y, Uchida K, Yamasaki T, Fujii Y, Okita K, Sakaida I. Improved liver function in patients with liver cirrhosis after autologous bone marrow cell infusion therapy. Stem Cells. 2006 Oct;24(10):2292-8. Epub 2006 Jun 15.</citation>
    <PMID>16778155</PMID>
  </reference>
  <reference>
    <citation>Kharaziha P, Hellström PM, Noorinayer B, Farzaneh F, Aghajani K, Jafari F, Telkabadi M, Atashi A, Honardoost M, Zali MR, Soleimani M. Improvement of liver function in liver cirrhosis patients after autologous mesenchymal stem cell injection: a phase I-II clinical trial. Eur J Gastroenterol Hepatol. 2009 Oct;21(10):1199-205. doi: 10.1097/MEG.0b013e32832a1f6c.</citation>
    <PMID>19455046</PMID>
  </reference>
  <reference>
    <citation>Dai LJ, Li HY, Guan LX, Ritchie G, Zhou JX. The therapeutic potential of bone marrow-derived mesenchymal stem cells on hepatic cirrhosis. Stem Cell Res. 2009 Jan;2(1):16-25. doi: 10.1016/j.scr.2008.07.005. Epub 2008 Aug 6. Review.</citation>
    <PMID>19383405</PMID>
  </reference>
  <reference>
    <citation>Abdel Aziz MT, Atta HM, Mahfouz S, Fouad HH, Roshdy NK, Ahmed HH, Rashed LA, Sabry D, Hassouna AA, Hasan NM. Therapeutic potential of bone marrow-derived mesenchymal stem cells on experimental liver fibrosis. Clin Biochem. 2007 Aug;40(12):893-9. Epub 2007 May 3.</citation>
    <PMID>17543295</PMID>
  </reference>
  <reference>
    <citation>Li C, Kong Y, Wang H, Wang S, Yu H, Liu X, Yang L, Jiang X, Li L, Li L. Homing of bone marrow mesenchymal stem cells mediated by sphingosine 1-phosphate contributes to liver fibrosis. J Hepatol. 2009 Jun;50(6):1174-83. doi: 10.1016/j.jhep.2009.01.028. Epub 2009 Mar 29. Erratum in: J Hepatol. 2009 Nov;51(5):973.</citation>
    <PMID>19398237</PMID>
  </reference>
  <reference>
    <citation>Kim TH, Kim JK, Shim W, Kim SY, Park TJ, Jung JY. Tracking of transplanted mesenchymal stem cells labeled with fluorescent magnetic nanoparticle in liver cirrhosis rat model with 3-T MRI. Magn Reson Imaging. 2010 Sep;28(7):1004-13. doi: 10.1016/j.mri.2010.03.047.</citation>
    <PMID>20663626</PMID>
  </reference>
  <reference>
    <citation>Rabani V, Shahsavani M, Gharavi M, Piryaei A, Azhdari Z, Baharvand H. Mesenchymal stem cell infusion therapy in a carbon tetrachloride-induced liver fibrosis model affects matrix metalloproteinase expression. Cell Biol Int. 2010 Apr 27;34(6):601-5. doi: 10.1042/CBI20090386.</citation>
    <PMID>20178458</PMID>
  </reference>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 25, 2010</study_first_submitted>
  <study_first_submitted_qc>November 2, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 3, 2010</study_first_posted>
  <last_update_submitted>February 19, 2016</last_update_submitted>
  <last_update_submitted_qc>February 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Sciences</investigator_affiliation>
    <investigator_full_name>Yufang Shi</investigator_full_name>
    <investigator_title>principal investigator</investigator_title>
  </responsible_party>
  <keyword>liver Cirrhosis</keyword>
  <keyword>Mesenchymal stem cells</keyword>
  <keyword>Hepatic artery infusion</keyword>
  <keyword>Intravenous infusion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

